期刊
CURRENT ONCOLOGY REPORTS
卷 21, 期 1, 页码 -出版社
SPRINGER
DOI: 10.1007/s11912-019-0750-1
关键词
Immune checkpoint blockade; Immuno-oncology; Combination therapy; Epacadostat; Indoximod; BMS-986205
类别
资金
- Canadian Cancer Society
- Liddy Shriver Sarcoma Initiative
Purpose of ReviewThis review focuses on the recent clinical development of indolamine-2,3-dioxygenase-1 (IDO-1) inhibitors.Recent FindingsIDO-1 alters tryptophan metabolism in a manner enhancing T-regulatory cell activity, but pre-clinical data show that its role in tumorigenesis is context-dependent on host and tumor interaction, highlighting some challenges in understanding the molecular oncology of this enzymatic drug target. Because results from phase I/II trials of IDO-1 inhibitor monotherapy have been disappointing, current clinical trials employ IDO-1 inhibitors in combination strategies with other immunotherapy agents or with chemotherapy radiation. Combinations with anti-PD-1/PD-L1 antibodies are already showing promise, and related strategies are under active evaluation.Summary While further research is needed to elucidate the precise role of IDO-1 in tumor development, its mechanisms of action appear sufficiently distinct from other immunotherapy targets to warrant inclusion in combination immunotherapy regimens, an approach where multiple clinical trials are currently underway.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据